📌 Key Takeaways
- Topic: How Is Silica Made? Production Methods for Each Type of Silica
- Keywords: silica for 3D printing
- Published: 2026-11-20 04:10:51
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Admatechs Silica: Submicron Spherical Silica Products and Applications
- Silicon Dioxide Structure: Tetrahedral Network and Crystal Forms Explained
- Due to the essential function of MSNs in the biomedical field, the timeline of some key achievements involving MSNs is presented in Fig. 3. Comparable to MCM-41, Santa Barbara Amorphous-15 (SBA-15) is also demonstrated to be another really promising nanomaterial in the biomedical field, which is a highly stable mesoporous silica sieve reported by scientists from the University of California at Santa Barbara in 1998. 47 Several years later, the first instance of biomedical applications involving mesoporous silica for drug delivery is reported. 48 MCM-41 is revealed to have the talent to load and deliver the anti-inflammatory drug, ibuprofen, with a weight percent ratio of 30%. 48 In the same year, researchers from two different research groups both reported that the particle size of MCM-41 could be tuned to the nanoscale, 49, 50 and its morphology could also be precisely designed. 50 These findings have greatly encouraged researchers to discuss the potential biomedical applications of MSNs. In 2003, Lai et al. explored the feasibility of MCM-41-type MSNs in controlled-release delivery systems, in which they used cadmium sulfide (CdS) NPs as chemically removable caps to encapsulate drug molecules into the pore channels of MSNs. 51 Subsequently, the disulfide bond-reducing molecules served as triggers to control the stimuli-responsive release of drug molecules including vancomycin and adenosine triphosphate. 51 In the meantime, the same research group also utilized polyamidoamines to modify the surface of MCM-41-type MSNs, and constructed a novel gene transfection system in 2004, which is the first study of the uptake behavior about MSNs into the eukaryotic cells. 52 Afterwards, Lin et al. developed fluorescein-labelled hexagonal crystal-like MSNs with a size of 110 nm as cell marker. 53 To fully exploit the physicochemical properties of MSNs and their potential for biomedical applications, in 2008, Liong et al. loaded superparamagnetic iron oxide into the internal pores of MSNs and subjected MSNs to phosphonate coating, targeting ligand modification and anti-cancer drug encapsulation, resulting in a multifunctional silica-based nanoplatform that can be used for imaging, targeting and drug delivery. 54 Since the degradability of MSNs is critical to the growth of nanoformulations with high safety, researchers continue to discuss the degradation behavior and mechanisms of MSNs. In 2010, a three-state degradation process of MSNs was proposed, which presented a new understanding of the degradation kinetic mechanism of MSNs that differs markedly from that of traditional non-porous silica-based materials. 55 Apart from, Lin et al. systematically shown the impact of MSNs with diverse particle size, pore structure and surface modification on hemolytic activity in 2010. 56 This pioneering work delivers advice for understanding the toxic influences of MSNs in vivo. In 2011, Cornell dots, which are silica-based hybrid NPs with a size of 6-10 nm, become the first FDA-approved nanoformulation for a first-in-human clinical trial. 57 The first-in-human clinical trial of 124 I-labelled Cornell dots showed that they can be applied to diagnose and stage tumors including melanoma and malignant brain cancer. 58 Furthermore, to obtain MSNs with rapid biodegradability, Zhao's group developed a biphase stratification method for preparing monodispersed three-dimensional dendritic MSNs (3D-dendritic MSNs). The as-prepared 3D-dendritic MSNs can degrade completely in the simulated biological medium within 24 h. 59 Over the past few years, with the outbreak and spread of coronavirus SARS-CoV-2, nanotechnology based on MSNs against coronavirus infection has also developed. In 2020, Balagna et al. conducted preliminary antiviral test toward SARS-CoV-2 by using the silver nanocluster/silica nanocomposite deposited onto facial masks. 60 In another work, a FDA-approved antiviral drug, niclosamide (NIC), was encapsulated into MSNs, followed by the coating with Tween 60. The MSNs-based nanocomposite was demonstrated to be a potential oral formulation for SARS-CoV-2. 61
- Alumina Powder vs Silica Powder: Properties, Uses and How to Choose
- Silica HS Code: Correct Customs Classification for Silica, Quartz and Silica Gel
- Silica Distributor vs Manufacturer: Which Is Better for Your Purchase?
- Lu, J. et al. BSA modified, disulfide-bridged mesoporous silica with low biotoxicity for dual-responsive drug delivery. Micropor. Mesopor. Mater. 278, 257-266 (2019). Article CAS Google Scholar
What Is Cristobalite? Properties, Uses and How It Differs from Quartz
What is silica (SiO₂)?
crystalline silica powder
What is the difference between fumed silica and precipitated silica?
HDK N20 Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.
What drives silica raw material prices?
silica supplier Japan Qiu, Z., Shu, J. & Tang, D. Bioresponsive release system for visual fluorescence detection of carcinoembryonic antigen from mesoporous silica nanocontainers mediated optical color on quantum dot-enzyme-impregnated paper. Anal. Chem. 89, 5152-5160 (2017). Piece CAS PubMed Google Scholar
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.